Press Room

CSF Europe 2024 - Compaction Simulation Forum

Start
Tuesday, June 04, 2024 - 16:49
End
Thursday, June 06, 2024 - 18:00
Location: Dublin, Ireland
CSF Conference João Henriques speaker | Hovione

CSF Workshop: Overcoming The Challenge of Poorly Soluble Drugs

This workshop delves into the complexities surrounding the formulation of poorly soluble drugs, a prevalent concern affecting a significant percentage of active pharmaceutical ingredients. Explore the scientific nuances of amorphous forms and their role in amorphous solid dispersions (ASDs), offering insights into enhanced solubility and dissolution. 

Our expert, João Henriques, Director, Oral Drug Product Development will lead the Workshop Session: Process Development and Scale-Up of Spray Drying

Join the session for an academic exploration where knowledge converges with scientific rigor, providing a thorough understanding of the formulation intricacies of poorly soluble drugs.

 

Key learnings:

  • Expand on your foundations and principles of spray drying for ASDs, from lab-scale development tools to the scale-up of processes and gain valuable insights on how ASDs improve the solubility and bioavailability of poorly soluble drugs.
  • Overcome solubility challenges with the best scale-up science, utilizing mechanistic and statistical modeling to delve into the impact of spray drying conditions and material attributes on downstream processing while leveraging our extensive expertise to ensure success from lab-scale to commercialization.

 

Do you want to know how Hovione can support your project? Schedule a meeting today.

schedule a meeting

 

 

 

 

Learn more about CSF Europe.

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026